Reply: Genetic heterogeneity of neuronal intranuclear inclusion disease. What about the infantile variant?
1 The authors provided a summary of all published cases of iNIID and has demonstrated that iNIID is a rapidly progressive neurodegenerative disorder across different ethnicities with complex phenotypes; the unifying features in these patients were ataxia and cerebellar atrophy. [...]dementia, neurop...
Saved in:
Published in | Annals of clinical and translational neurology Vol. 8; no. 4; pp. 1002 - 1004 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United States
John Wiley & Sons, Inc
01.04.2021
John Wiley and Sons Inc Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | 1 The authors provided a summary of all published cases of iNIID and has demonstrated that iNIID is a rapidly progressive neurodegenerative disorder across different ethnicities with complex phenotypes; the unifying features in these patients were ataxia and cerebellar atrophy. [...]dementia, neuropathy, myopathy, leukoencephalopathy and other movement disorders are more common clinical manifestations of juvenile and adult‐onset NIID carrying the GGC repeat expansion in NOTCH2NLC and their disease course usually spans decades. 2,3 Although neuronal intranuclear inclusions were found throughout tissues in the nervous system and other organs, patients with iNIID do not have typical MRI findings of hyperintensity in the corticomedullary junction on diffusion‐weighted sequences and typical NIIs on skin biopsy. The clinical disease heterogeneity can be seen in other repeat expansion disorders such as spinocerebellar ataxia 3: a larger CAG repeat expansion manifests with childhood‐onset spasticity and parkinsonism without ataxia whilst a shorter repeat allele causes ataxia and peripheral neuropathy at a later age. 7,8 However, we agree with Sikora et al that iNIID may also be a distinct genetic disorder to juvenile and adult‐onset NIID. |
---|---|
Bibliography: | W.Y.Y. receives a PhD studentship from Ataxia UK and Rosetree Trust and funding from a Nicholas Blair MDSANZ traveling fellowship. R.S. receives funding from MRC. Z.C. is supported by a clinical fellowship from the Leonard Wolfson Foundation. We are grateful to the Medical Research Council (MRC), The Wellcome Trust Synaptopathies award, MRC Centre grant (G0601943), Ataxia UK, The Rosetrees Trust, Brain Research UK, UCL ODA/LMIC award, The MSA Trust, MDUK, The Muscular Dystrophy Association (MDA). This research was also supported by the UCL/UCLH National Institute for Health Research University College London Hospitals Biomedical Research Centre. Funding Information SourceType-Other Sources-1 content type line 63 ObjectType-Correspondence-1 ObjectType-Commentary-2 ObjectType-Article-3 |
ISSN: | 2328-9503 2328-9503 |
DOI: | 10.1002/acn3.51330 |